Prostate cancer is the 2nd most common cancer in men.
1 IN 8 MEN WILL GET IT IN THEIR LIFETIME…
…but prostate cancer diagnosis and treatment have major limitations.
PreView Medical has developed two systems to improve detection and precisely locate and treat prostate cancer:
The ClariCore® Biopsy System uses AI-powered Spectroscopy to classify tissue as benign or suspicious in real time during a prostate biopsy.
In a standard biopsy, tissue samples are taken randomly from the prostate and evaluated by pathology. This approach can miss almost half of all cancers.
With ClariCore®, a needle is inserted and, before tissue samples are taken, spectroscopy is performed. Integrated fiber optics shine light of specific wavelengths into the tissue.
The returned light is instantaneously analyzed by a spectrometer and an AI algorithm, classifying the tissue as benign or suspicious. This has the potential to find more cancers.
In a 144 patient multi-center study, ClariCore® was shown to have very high accuracy in classifying tissue:
NEGATIVE PREDICTIVE VALUE